8:20 am Chair’s Opening Remarks

8:30 am Engaging Immune Cells While Limiting Toxicity


  • What’s new in the T and NK cell engager field
  • Ideas from some T and NK cell engagers in development

9:00 am PANEL DISCUSSION: Where Are We Now & Where Are We Going?


This panel will set out to address

  • Where have the current cytokine engineering strategies taken us and what can we learn from this?
  • Assessing the latest clinical work with lesser known and novel cytokines
  • Assessing the fields biggest roadblocks for moving current promising pre-clinical candidates into the clinic
  • Assessing the role of combination therapies with cytokine targeted therapies? – Where is there proven synergy?

9:45 am
Morning Networking


Join us for face-to-face networking. We will pair you up with fellow attendees so you can get one on one time with the brightest minds working in the cytokine field for you to establish meaningful relationships.

10:15 am
Refreshment Break

An Update from the Clinic: Success & Failure at the Front of the Field

10:30 am Presentation Slot Reserved for The Jackson Laboratory

11:00 am Targeting IL-2 to tumor-specific T cells with novel biologic platforms

  • Raymond Moniz Associate Director- Discovery & Translational Immunology, Cue Biopharma


  • Generating a therapeutic index for IL-2 via selective delivery to tumor-specific T cells demonstrates anti-tumor activity in cancer patients
  • Lead clinical candidate, CUE-101, provides clinical PoC and de-risking for the Immuno-STAT platform
  • Novel bispecifics that can re-direct the protective viral T cell repertoire to destroy cancers – potential for superior safety and clinical efficacy

11:30 am IL-7 therapy: Oncology and beyond

  • Byung Lee Senior Vice President & Chief Scientific Officer, NeoImmuneTech Inc.


  • NT-I7 (efineptakin alfa, a long-acting human IL-7) clinical development
  • NT-I7 in combination with checkpoint inhibitors
  • Potential clinical biomarkers in IL-7 treatment

12:00 pm Co-Stimulation of Adaptive and Innate Immune Cells to Achieve Clinical Benefit with MDNA11, a Long-Acting ‘Beta-only’ IL-2 Super-Agonist

  • Fahar Merchant President & Chief Executive Officer, Medicenna Therapeutics


  • MDNA11 is an albumin fusion to a variant of IL-2 bestowed with enhanced affinity for CD122 and deprived of CD25 binding, with the intent to selectively stimulate immune effector cells. The presentation will comprise:
  • Preliminary results from the ongoing MDNA11 Phase 1/2 ABILITY Clinical Trial in patients with advanced solid tumors
  • Emerging safety and clinical benefit as we establish the recommended phase 2 dose (RP2D) and schedule during monotherapy dose-escalation, and
  • Compare the PK profile and PD response of MDNA11 within the IL-2 class of immuno-therapies for oncology

12:30 pm
Lunch & Networking Break

A Deep Dive into Pre-Clinical Development Challenges & Opportunities

1:30 pm Presentation Slot Reserved for Promega

2:00 pm Intratumoral mRNA Approach to Delivering Cytokine Immunotherapies

  • Paula Fraenkel Executive Director & Global Project Lead, AstraZeneca


  • Comparison to other approaches
  • MEDI1191: IL12 mRNA mechanism of action and preclinical data
  • Update of clinical, safety, and translational data from ongoing first-in-human clinical trial in combination with durvalumab

2:30 pm Clinically translatable cytokine delivery platform for cancer immunotherapy


  • Describe the development of the LOCOcyteTM, an allogeneic cell-based immunotherapy platform to enable potent localized modulation of the immune system which also precipitates a systemic immune response for cancer immunotherapy
  • Highlight pre clinical data with our LOCOcyteTM platform demonstrating tumor eradication in advanced ovarian cancer, colorectal, and mesothelioma cancer mouse models. Review non human primate safety, pharmacokinetics, and pharmacodynamic data with our LOCOcyteTM platform
  • Describe clinical synopsis of LOCOcyteTM first in human trial for advanced recurrent ovarian cancer patients

3:00 pm Presentation Slot Reserved for Eurofins

3:30 pm
Afternoon Break

4:00 pm The role of PKPD modelling for cytokine-based therapies: challenges and future perspectives

  • Glareh Azadi Principal Scientist - Translational Pharmacokinetic-Pharmacodynamic & Modeling , Abbvie


  • Importance of mathematical models to describe PKPD relationship for cytokine-based therapies summary of available models and key data needed for model building
  • Future perspective on how this field can be enriched with relevant mathematical models

Strategies to Ensure Localizing Activity into the Tumor

4:30 pm Exploring the potential of a multi-cytokine delivery system to develop more effective cancer therapies


  • Development and interrogation of a gold nanoparticle cytokine delivery system
  • Use of a cytokine powered platform to generation multi-modal cancer therapies
  • Improving key metrics of cytokine delivery including PK, tumor uptake and safety using a nanoparticle delivery system

5:00 pm Chairs Closing Remarks

5:10 pm End of Day 1